Resultados globales: 2 registros encontrados en 0.03 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
8 p, 412.5 KB Subgroup analysis in RAISE : a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression / Obermannová, R. (Masaryk Memorial Cancer Institute (Czech Republic)) ; Van Cutsem, E. (KU Leuven. University Hospitals Leuven (Belgium)) ; Yoshino, T. (National Cancer Center Hospital East (Japan)) ; Bodoky, G. (St László Hospital (Hungary)) ; Prausová, J. (Charles University. Onocology Clinic (Czech Republic)) ; Garcia-Carbonero, R. (Hospital Universitario Doce de Octubre) ; Ciuleanu, T. (Institutul Oncologic Ion Chiricuta and UMF (Romania)) ; Garcia Alfonso, P. (Hospital General Universitario Gregorio Maraňón) ; Portnoy, D. (The University of Tennessee. Health Science Center (USA)) ; Cohn, A. (Rocky Mountain Cancer Center (USA)) ; Yamazaki, K. (Shizouka Cancer Center (Japan)) ; Clingan, P. (Southern Medical Day Care Centre (Australia)) ; Lonardi, S. (Istituto Oncologico Veneto-IRCCS (Italy)) ; Kim, T. W. (University of Ulsan College of Medicine. Asan Medical Center (South Corea)) ; Yang, L. (Eli Lilly and Company (USA)) ; Nasroulah, F. (Eli Lilly and Company (República Argentina)) ; Tabernero Caturla, Josep (Institut d'Oncologia de la Vall Hebron (VHIO)) ; Universitat Autònoma de Barcelona
The RAISE phase III trial demonstrated ramucirumab + FOLFIRI improved survival compared with placebo + FOLFIRI for second-line metastatic colorectal carcinoma patients previously treated with first-line bevacizumab, oxaliplatin, and a fluoropyrimidine. [...]
2016 - 10.1093/annonc/mdw402
Annals of Oncology, Vol. 27, Issue 11 (November 2016) , p. 2082-2090  
9 p, 1023.2 KB Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain : results of a subgroup analysis of the phase 3 RECOURSE trial / Longo Muñoz, Federico (Hospital Universitario Ramón y Cajal) ; Argilés Martínez, Guillem (Hospital Universitari Vall d'Hebron) ; Tabernero Caturla, Josep (Hospital Universitari Vall d'Hebron) ; Cervantes, A. (Universitat de València) ; Grávalos, Cristina (Hospital Universitario Doce de Octubre) ; Pericay, Carles (Corporació Sanitària Parc Taulí) ; Gil Calle, S. (Hospital Carlos Haya) ; Mizuguchi, Hirokazu (Taiho Oncology) ; Carrato, Alfredo (Hospital Universitario Ramón y Cajal) ; Limón, María Luisa (Hospital Universitario Virgen del Rocío) ; García Carbonero, Rocio (Hospital Universitario Doce de Octubre) ; Universitat Autònoma de Barcelona
TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. [...]
2017 - 10.1007/s12094-016-1528-7
Clinical & Translational Oncology, Vol. 19, Issue 2 (February 2017) , p. 227-235  

Vea también: autores con nombres similares
2 Garcia-Carbonero, R
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.